HEOR Services Market Intelligence

A comprehensive HEOR Services Market Report that answers these questions

A comprehensive HEOR Services Market Report that answers these questions

  • What are the key trends in HEOR Services category?
  • Am I paying the right price?
  • Am I working with the right supplier?
  • What are the major challenges and risks in HEOR Services industry?
  • How is HEOR Services industry performing?

Over 50,000+ users trust Beroe

Report Coverage

  • HEOR Acquisitions by Geography
  • Mergers and Acqusitions
  • Cost Break-up Analysis

Market Size

CAGR

10-15 Percent

Market Size North America

$312 Mn

Market Size Europe

$ 351 Mn

Market Size Asia Pacific

$ 78 Mn

Table of contents

  1. HEOR Services Executive Summary
  2. Executive Summary
  3. BREXIT Impact Update
  1. HEOR Services Market Analysis
  2. Market Overview
  3. Drivers and Constraints
  4. Market Trends
  5. Porter’s Five Forces Analysis
  6. Outsourcing Adoption Rate
  1. HEOR Services Supply Analysis
  2. Supplier Landscape
  3. Mergers & Acquisitions
  4. Major Suppliers: CROs
  5. Major Suppliers: Non-CROs
  1. HEOR Services IndustryBest Practices
  2. Sourcing Model
  3. Engagement Strategy
  4. Pricing Model
  5. Competitive Intelligence
  1. HEOR Services Quick Reference
  2. Expert Profile

Want a more detailed personalised report?

HEOR Services Market Growth and Global Outlook

  • The HEOR market is growing at a reasonable pace, as the level of outsourcing is high in this category. The market is seen to be heavily consolidating with newer players, like private equity and data analytics company coming into HEOR space. The industry is also witnessing regulations, which require greater real-world evidence and outcome data, which is resulting in the entry of disruptive innovations, like big-data analytics, m-health, bioinformatics, and other patient intelligence technologies
  • Increasing requirement of evidence-based approach as well as increasing demand for outcomes research is fuelled by the increased need for Real-world Evidence (RWE) to demonstrate the value of the drug, driven by regulatory/pricing authorities
  • Increase in the number of drugs in large pharma product pipeline and requirement for orphan drugs to target the unmet medical needs of patients are the key factors increasing the demand to study the market for potential and effective pricing of the product
  • The market is expected to grow further, mainly due to the increasing requirement of evidence-based approach to demonstrate the value of the drug
  • Entry of disruptive technologies, like big data analytics and m-health, are expected to increase in the future, as more HTA organizations around the world require real-world evidence
  • Europe and North America hold the major HEOR market share, 45% and 40% respectively as the availability of experienced market researchers and outcome research-based specialists with proven track records are high within the pharma sector
  • The HEOR market is growing at a reasonable pace, as the level of outsourcing is high in this category. The HEOR market size grew at a CAGR of 10-15% from 2012-2017
  • HEOR and RWE are interlinked as mandatory HTA submission requirement and growing impact of real-world evidence in P&R are the key drivers of outsourcing.

heor-services-global-market-size

  • Increase in the number of drugs in large pharma product pipeline and requirement for orphan drugs to target the unmet medical needs of patients are the key factors increasing the demand to study the market for potential and effective pricing of the product
  • The market is expected to grow further, mainly due to the increasing requirement of evidence-based approach to demonstrate the value of the drug
  • Entry of disruptive technologies, like big data analytics and m-health, are expected to increase in the future, as more HTA organizations around the world require real-world evidenc

Growth Drivers and Constraints

Drivers

  • Real-world evidence and outcome data for reimbursement
  • Increasing demand for showcasing value of the drug
  • Mandatory HTA submission in many countries
  • Pharma being forced to go beyond their comfort zone, like using big-data analytics and m-health technologies, which is driving outsourcing to a large extent
  • Pricing control forcing pharma to invest in substantiating their case (commercial trials)
  • Cost cutting within pharma, leading to increased outsourcing of these services without increasing the head count

Constraints

  • Lack of experience in using genomics, determining sub-group populations for effective outcome demonstration
  • Lack of a standardization of HTA requirements
  • Pharma in nascent stages of contracting in their non-core areas, like m-health and big data
  • Many countries lack mandatory HTA

Outsourcing Adoption Rate

  • Outsourcing is well established and a matured trend in this industry
  • Manpower cost is an issue (for small/mid-size pharma companies)
  •  Novel outsourcing for big data analytics is the new trend. E.g. Pfizer outsourcing real-world evidence data analytics to Optum in 2014
  • Large pharma companies conduct 30 - 50 percent of trial in-house that provide them with evidence/outcome data freely, eliminating a need for third-party players for those specific data
  • The major reason for greater outsourcing in this market is because of varying needs of each study, depending on competition, market, and disease
  • CROs are improving their value proposition by providing HEOR as an integrated service along with clinical trials, which can be as negotiation lever for pharma in a bundle
  • In the future, this category will see entry of disruptive technologies, like big data analytics and m-health, as more HTA organizations around the world require real-world evidence

HEOR Services Top Suppliers

  • IQVIA
  • Xcenda
  • LASER ANALYTICA
  • RTI International

Market Overview

  • The entry of big data analytics, m-health, and other patient analytics tools has been the major trend in the HEOR market. Market is still in infancy with respect to adoption of HEOR services early on in the clinical trials and P&R is the biggest concern for the pharma companies.
  • RWE data demand is increasing over time as players such as insurance companies are demanding huge amount of data defining value and effectiveness of medicines
  • There are three types of service providers: academic, consultants, and CROs. Of the three, consultants and CROs are preferred over academicians, as the latter have little experience in real-world drug development and cannot scale to large trials
  • In the future, as a result of supply base consolidation, pharma companies would engage through strategic partnerships with full-service HEOR and RWE providers rather than specialist for each sub category.

Why You Should Buy This Report

  • The report details the pricing models, supplier landscape and outsourcing adoption rate for the HEOR market. 
  • Information about what is HEOR, HEOR full form, global HEOR market size, emerging markets, drivers, constraints, etc. 
  • Porter’s five force analysis of the HEOR industry
  • It shows the key market trends like novel partnerships, new technologies, full-service providers and emergence of biologics.

Complimentary 12-month access to Beroe LiVE

Any more questions?

Get in touch with us quickly and easily.